Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for
allogeneic SCT?
Collaboration with Hematology and Bone Marrow Transplantation Unit research group in molecular diagnostics applied to the management of patients undergoing
allogeneic SCT, especially for the detection of minimal residual disease and early relapse.
The subindication for which now data were available for the first time was
allogeneic SCT with related donor in comparison with
allogeneic SCT with unrelated donor.
Not exact matches
Horwitz et al 79 reported that donor MSC contributed to bone remodelling after
allogeneic stem cell transplantation (
SCT) in 3 children with osteogenesis imperfecta, a rare genetic disorder of type I collagen.
Ponatinib Extends Survival Over Transplant in Chronic Phase CML: The results of a new study that included patients from the PACE trial and the European Bone Marrow Transplant registry revealed that treatment with ponatinib yielded better overall survival (OS) compared with
allogeneic stem cell transplantation (allo -
SCT) in patients with chronic phase chronic myeloid leukemia (CP - CML) with a T315I mutation.